1. 1 © 2012 Ipsos © 2014 Ipsos. All rights reserved. Contains Ipsos' Confidential and Proprietary information and may not be disclosed or reproduced without the prior written consent of Ipsos. Trended surveillance of HIV epidemiology in MSM across the EU5 BACKGROUND: Examine how MSM antiretroviral treatment adoption has evolved Identify MSM population-specific differences relative to all HIV patients METHOD: Syndicated HIV Therapy Monitor and Scope studies Running since 1996 Collect data from 230 physicians across the EU5 Physicians report on patients seen within each study period Samantha Fernando PhD

2. 2 © 2012 Ipsos NICE PH34 guideline change European AIDS Clinical Society guideline change WHO guideline change RESULTS: HIV guideline changes in the EU5 Source: Ipsos HIV Monitor EU5Source: Ipsos HIV Scope EU5

3. 3 © 2012 Ipsos Country specific 14Q1 MSM data MSM relative to all patients in the 5EU are more responsive to starting treatment Earlier capture and treatment initiation is imperative to suppress viral load, increasing future treatment success and controlling HIV progression amongst this high-risk group Source: Ipsos HIV Scope EU5 Length of time between diagnosis and initiation of first line therapy CONCLUSIONS: A marked shift in MSM treatment adoption